We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$771M
AUM Growth
-$198M
Cap. Flow
-$50.7M
Cap. Flow %
-6.57%
Top 10 Hldgs %
57.03%
Holding
73
New
7
Increased
16
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$40.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.7M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$21.1M
4
ASND icon
Ascendis Pharma A/S
ASND
+$20.3M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$19.2M

Top Sells

Rank Stock Value
1
ALGS icon
Aligos Therapeutics
ALGS
+$36.9M
2
RPTX
Repare Therapeutics
RPTX
+$35.9M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$22.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$15.5M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPSC icon
26
Century Therapeutics
IPSC
$377M
$6.93M 0.9%
550,259
-63,836
-10% -$846K
CNTA
27
DELISTED
Centessa Pharmaceuticals
CNTA
$4.08M 0.53%
454,545
– –
TIL icon
28
Instil Bio
TIL
$48.5M
$4.05M 0.53%
+18,855
New +$4.41M
TRML
29
DELISTED
Tourmaline Bio
TRML
$3.01M 0.39%
30,624
-2,277
-7% -$213K
TYRA icon
30
Tyra Biosciences
TYRA
$1.85B
$2.7M 0.35%
252,726
-220,668
-47% -$2.62M
VERV
31
DELISTED
Verve Therapeutics
VERV
$2.21M 0.29%
96,912
-346,353
-78% -$9.9M
CGEM icon
32
Cullinan Oncology
CGEM
$1.07B
$2.09M 0.27%
200,000
-88,458
-31% -$1.2M
EWTX icon
33
Edgewise Therapeutics
EWTX
$4.48B
$2.07M 0.27%
213,744
-636,256
-75% -$8.19M
SPRB
34
Spruce Biosciences
SPRB
$116M
$2.01M 0.26%
13,333
-1,334
-9% -$248K
NUVL
35
DELISTED
Nuvalent
NUVL
$1.87M 0.24%
134,650
– –
LIAN
36
DELISTED
LianBio American Depositary Shares
LIAN
$1.53M 0.2%
412,837
– –
VRNA
37
DELISTED
Verona Pharma
VRNA
$1.5M 0.19%
300,000
+178,000
+146% +$1.04M
VIGL
38
DELISTED
Vigil Neuroscience
VIGL
$1.45M 0.19%
+205,595
New +$2.71M
VTGN icon
39
VistaGen Therapeutics
VTGN
$9.45M
$1.24M 0.16%
33,333
-33,334
-50% -$1.45M
PYXS icon
40
Pyxis Oncology
PYXS
$184M
$1.16M 0.15%
286,652
– –
COGT icon
41
Cogent Biosciences
COGT
$6.91B
$1.12M 0.15%
150,000
– –
IMA
42
ImageneBio Inc
IMA
$63.2M
$1.09M 0.14%
14,857
-10,131
-41% -$1.08M
BMEA icon
43
Biomea Fusion
BMEA
$91.1M
$892K 0.12%
200,000
-52,320
-21% -$339K
SLGC
44
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$802K 0.1%
100,000
-100,493
-50% -$886K
RAIN
45
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$680K 0.09%
134,194
-110,967
-45% -$890K
OMGA
46
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$81K 0.01%
12,986
-75,249
-85% -$768K
NUVB.WS
47
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$54K 0.01%
66,666
– –
ALGS icon
48
Aligos Therapeutics
ALGS
$25.2M
– –
-124,511
Closed -$36.9M
ALNY icon
49
Alnylam Pharmaceuticals
ALNY
$37.2B
– –
-35,000
Closed -$5.93M
CMPS
50
Compass Pathways
CMPS
$1.52B
– –
-300,000
Closed -$6.63M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2022 Portfolio in Review

As of Q1 2022, Logos Global Management held 73 positions worth $771M, down 20% from $970M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Logos Global Management withdrew a net $50.7M in Q1 2022, closing 26 positions and reducing 17 holdings. Its most notable exit was Aligos Therapeutics, an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Neurocrine Biosciences worth $44.5M.

  • Logos Global Management's largest Q1 2022 buy was Neurocrine Biosciences: 475,000 shares worth $44.5M.
  • Logos Global Management added most to Mirati Therapeutics, Inc. Common Stock in Q1 2022, an estimated $30.7M increase.
  • Logos Global Management's biggest Q1 2022 reduction was Verve Therapeutics, cutting an estimated $9.9M.
  • Logos Global Management fully exited Aligos Therapeutics in Q1 2022, selling an estimated $36.9M.
  • Logos Global Management's ten largest holdings make up 57% of its $771M portfolio in Q1 2022.
  • Logos Global Management opened 7 new positions and closed 26 in Q1 2022.
  • Logos Global Management's portfolio value fell 20% quarter-over-quarter to $771M.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.